{"id":2460,"date":"2020-05-28T08:55:48","date_gmt":"2020-05-28T08:55:48","guid":{"rendered":"https:\/\/rhepa.se\/?p=2460"},"modified":"2020-06-04T07:17:38","modified_gmt":"2020-06-04T07:17:38","slug":"urdmark-battre-lage-for-biotechaktier","status":"publish","type":"post","link":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/","title":{"rendered":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier"},"content":{"rendered":"<p>Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman &amp; Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn.<\/p>\n<p><strong><a href=\"https:\/\/www.avanza.se\/placera\/redaktionellt\/2020\/05\/28\/urdmark-battre-lage-for-biotechaktier.html\">Se f\u00f6rvaltarintervju h\u00e4r<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman &amp; Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r<\/p>","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-2460","post","type-post","status-publish","format-standard","hentry","category-rhenman_partners"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.2 - aioseo.com -->\n\t<meta name=\"description\" content=\"Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman &amp; Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Rhepa\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.2\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_GB\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Rhenman &amp; Partners - Asset Management AB\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier - Rhenman &amp; Partners\" \/>\n\t\t<meta property=\"og:description\" content=\"Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman &amp; Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-05-28T08:55:48+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2020-06-04T07:17:38+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier - Rhenman &amp; Partners\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman &amp; Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#blogposting\",\"name\":\"Urdmark: B\\u00e4ttre l\\u00e4ge f\\u00f6r biotechaktier - Rhenman & Partners\",\"headline\":\"Urdmark: B\\u00e4ttre l\\u00e4ge f\\u00f6r biotechaktier\",\"author\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/author\\\/rhepa\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/rhepa.se\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/R-et.svg\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#articleImage\"},\"datePublished\":\"2020-05-28T08:55:48+00:00\",\"dateModified\":\"2020-06-04T07:17:38+00:00\",\"inLanguage\":\"en-GB\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#webpage\"},\"articleSection\":\"Rhenman &amp; Partners\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rhepa.se\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/category\\\/rhenman_partners\\\/#listItem\",\"name\":\"Rhenman &amp; Partners\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/category\\\/rhenman_partners\\\/#listItem\",\"position\":2,\"name\":\"Rhenman &amp; Partners\",\"item\":\"https:\\\/\\\/rhepa.se\\\/en\\\/category\\\/rhenman_partners\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#listItem\",\"name\":\"Urdmark: B\\u00e4ttre l\\u00e4ge f\\u00f6r biotechaktier\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#listItem\",\"position\":3,\"name\":\"Urdmark: B\\u00e4ttre l\\u00e4ge f\\u00f6r biotechaktier\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/category\\\/rhenman_partners\\\/#listItem\",\"name\":\"Rhenman &amp; Partners\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#organization\",\"name\":\"Rhenman & Partners\",\"description\":\"Asset Management AB Driven by Passion. Powered by Science. Asset Management AB\",\"url\":\"https:\\\/\\\/rhepa.se\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/rhepa.se\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/R-et.svg\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/\",\"https:\\\/\\\/x.com\\\/\",\"https:\\\/\\\/instagram.com\\\/\",\"https:\\\/\\\/pinterest.com\\\/\",\"https:\\\/\\\/youtube.com\\\/\",\"https:\\\/\\\/linkedin.com\\\/in\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/author\\\/rhepa\\\/#author\",\"url\":\"https:\\\/\\\/rhepa.se\\\/en\\\/author\\\/rhepa\\\/\",\"name\":\"Rhepa\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5ef45b8ea9603ab473b52db77c86d7358a598fe3eac31f63d2cac5f325e6f6dc?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Rhepa\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#webpage\",\"url\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/\",\"name\":\"Urdmark: B\\u00e4ttre l\\u00e4ge f\\u00f6r biotechaktier - Rhenman & Partners\",\"description\":\"Susanna Urdmark, f\\u00f6rvaltare p\\u00e5 Rhenman & Partners, ber\\u00e4ttar om den senaste utvecklingen inom h\\u00e4lsov\\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \\u00e4ven ett samtal om de generella f\\u00f6ruts\\u00e4ttningarna f\\u00f6r sektorn. Se f\\u00f6rvaltarintervju h\\u00e4r\",\"inLanguage\":\"en-GB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/urdmark-battre-lage-for-biotechaktier\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/author\\\/rhepa\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/author\\\/rhepa\\\/#author\"},\"datePublished\":\"2020-05-28T08:55:48+00:00\",\"dateModified\":\"2020-06-04T07:17:38+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/rhepa.se\\\/en\\\/\",\"name\":\"Rhenman & Partners\",\"description\":\"Asset Management AB\",\"inLanguage\":\"en-GB\",\"publisher\":{\"@id\":\"https:\\\/\\\/rhepa.se\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier - Rhenman & Partners","description":"Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman & Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r","canonical_url":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#blogposting","name":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier - Rhenman & Partners","headline":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier","author":{"@id":"https:\/\/rhepa.se\/en\/author\/rhepa\/#author"},"publisher":{"@id":"https:\/\/rhepa.se\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg","@id":"https:\/\/rhepa.se\/en\/#articleImage"},"datePublished":"2020-05-28T08:55:48+00:00","dateModified":"2020-06-04T07:17:38+00:00","inLanguage":"en-GB","mainEntityOfPage":{"@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#webpage"},"isPartOf":{"@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#webpage"},"articleSection":"Rhenman &amp; Partners"},{"@type":"BreadcrumbList","@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/rhepa.se\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/rhepa.se\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/rhepa.se\/en\/category\/rhenman_partners\/#listItem","name":"Rhenman &amp; Partners"}},{"@type":"ListItem","@id":"https:\/\/rhepa.se\/en\/category\/rhenman_partners\/#listItem","position":2,"name":"Rhenman &amp; Partners","item":"https:\/\/rhepa.se\/en\/category\/rhenman_partners\/","nextItem":{"@type":"ListItem","@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#listItem","name":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier"},"previousItem":{"@type":"ListItem","@id":"https:\/\/rhepa.se\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#listItem","position":3,"name":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier","previousItem":{"@type":"ListItem","@id":"https:\/\/rhepa.se\/en\/category\/rhenman_partners\/#listItem","name":"Rhenman &amp; Partners"}}]},{"@type":"Organization","@id":"https:\/\/rhepa.se\/en\/#organization","name":"Rhenman & Partners","description":"Asset Management AB Driven by Passion. Powered by Science. Asset Management AB","url":"https:\/\/rhepa.se\/en\/","logo":{"@type":"ImageObject","url":"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg","@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#organizationLogo"},"image":{"@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#organizationLogo"},"sameAs":["https:\/\/facebook.com\/","https:\/\/x.com\/","https:\/\/instagram.com\/","https:\/\/pinterest.com\/","https:\/\/youtube.com\/","https:\/\/linkedin.com\/in\/"]},{"@type":"Person","@id":"https:\/\/rhepa.se\/en\/author\/rhepa\/#author","url":"https:\/\/rhepa.se\/en\/author\/rhepa\/","name":"Rhepa","image":{"@type":"ImageObject","@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/5ef45b8ea9603ab473b52db77c86d7358a598fe3eac31f63d2cac5f325e6f6dc?s=96&d=mm&r=g","width":96,"height":96,"caption":"Rhepa"}},{"@type":"WebPage","@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#webpage","url":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/","name":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier - Rhenman & Partners","description":"Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman & Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r","inLanguage":"en-GB","isPartOf":{"@id":"https:\/\/rhepa.se\/en\/#website"},"breadcrumb":{"@id":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/#breadcrumblist"},"author":{"@id":"https:\/\/rhepa.se\/en\/author\/rhepa\/#author"},"creator":{"@id":"https:\/\/rhepa.se\/en\/author\/rhepa\/#author"},"datePublished":"2020-05-28T08:55:48+00:00","dateModified":"2020-06-04T07:17:38+00:00"},{"@type":"WebSite","@id":"https:\/\/rhepa.se\/en\/#website","url":"https:\/\/rhepa.se\/en\/","name":"Rhenman & Partners","description":"Asset Management AB","inLanguage":"en-GB","publisher":{"@id":"https:\/\/rhepa.se\/en\/#organization"}}]},"og:locale":"en_GB","og:site_name":"Rhenman &amp; Partners - Asset Management AB","og:type":"article","og:title":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier - Rhenman &amp; Partners","og:description":"Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman &amp; Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r","og:url":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/","og:image":"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg","og:image:secure_url":"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg","article:published_time":"2020-05-28T08:55:48+00:00","article:modified_time":"2020-06-04T07:17:38+00:00","twitter:card":"summary_large_image","twitter:title":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier - Rhenman &amp; Partners","twitter:description":"Susanna Urdmark, f\u00f6rvaltare p\u00e5 Rhenman &amp; Partners, ber\u00e4ttar om den senaste utvecklingen inom h\u00e4lsov\u00e5rdssektorn. Det blir givetvis mycket diskussion om forskningen kring covid-19 men \u00e4ven ett samtal om de generella f\u00f6ruts\u00e4ttningarna f\u00f6r sektorn. Se f\u00f6rvaltarintervju h\u00e4r","twitter:image":"https:\/\/rhepa.se\/wp-content\/uploads\/2025\/02\/R-et.svg"},"aioseo_meta_data":{"post_id":"2460","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-02-07 22:21:49","updated":"2025-09-07 16:22:12","focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/rhepa.se\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/rhepa.se\/en\/category\/rhenman_partners\/\" title=\"Rhenman &amp; Partners\">Rhenman &amp; Partners<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tUrdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/rhepa.se\/en\/"},{"label":"Rhenman &amp; Partners","link":"https:\/\/rhepa.se\/en\/category\/rhenman_partners\/"},{"label":"Urdmark: B\u00e4ttre l\u00e4ge f\u00f6r biotechaktier","link":"https:\/\/rhepa.se\/en\/urdmark-battre-lage-for-biotechaktier\/"}],"_links":{"self":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/2460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/comments?post=2460"}],"version-history":[{"count":7,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/2460\/revisions"}],"predecessor-version":[{"id":2467,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/posts\/2460\/revisions\/2467"}],"wp:attachment":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/media?parent=2460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/categories?post=2460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/tags?post=2460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}